Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus ORBACTIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus ORBACTIV.
FORBAXIN vs ORBACTIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, disrupting transglycosylation and transpeptidation. It also disrupts bacterial membrane integrity and causes depolarization, leading to cell death.
IV: 500 mg every 12 hours, infused over 30 minutes.
1200 mg IV once daily for 3 days
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is approximately 15.1 hours in healthy adults; in patients with renal impairment, half-life is prolonged (up to 28 hours in severe renal impairment).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily renal excretion as unchanged drug (approximately 33% of administered dose) and via biliary/fecal elimination (~50% recovered in feces as parent drug and metabolites).
Category C
Category C
Antibiotic
Antibiotic